The albumin paclitaxel class of drugs is the cornerstone class in the chemotherapeutic process of breast cancer. Commonly used paclitaxel analogs include regular paclitaxel, second-generation docetaxel, and the more recent albumin paclitaxel. Because paclitaxel analogs are characteristically lipophilic and insoluble in water, these drugs require polyoxyethylene, castor oil, and anhydrous ethanol as co-solvents. Because these co-solvents can cause allergic reactions, the application of paclitaxel-like drugs will be preceded by routine anti-allergic treatment, which also limits their use in clinical practice. In contrast, albumin paclitaxel is based on paclitaxel, and the incidence of allergic reactions is reduced when paclitaxel-like drugs are wrapped in albumin particles with nanotechnology. Therefore, pretreatment with dexamethasone is not required before using albumin paclitaxel, which also reduces the allergic reactions to paclitaxel-like drugs. Albumin paclitaxel also produces higher paclitaxel concentrations locally in the tumor and has a shorter injection time. Albumin paclitaxel can penetrate into the cells through the albumin receptors, which increases the concentration of the drug in the tumor and provides a better chemotherapeutic effect.